Effect of Indacaterol on Dynamic Lung Hyperinflation and Breathlessness in Hyperinflated Patients with COPD

REFERENCES

• Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Diagnosis, Management, and Prevention of COPD (updated 2009). Available at http: //www.goldcopd.com/ (accessed 14 Jan 2010).
   Google Scholar
• Cazzola M, Matera MG, Lotvall J. Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2005; 14: 775–783.
   PubMed Web of Science ®Google Scholar
• Feldman G, Siler T, Prasad N, Jack D, Piggott S, Owen R, Higgins M, Kramer B. Efficacy and safety of indacaterol 150 mcg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med 2010; 10:11.
   PubMed Web of Science ®Google Scholar
• Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, Bleasdale P, Owen R, Higgins M, Kramer B, on behalf of the INVOLVE (indacaterol: value in COPD pulmonary disease: longer term validation of efficacy and safety) study investigators. Efficacy of a new once-daily LABA, indacaterol, versus the twice-daily LABA, formoterol, in COPD. Thorax 2010; 65:473–479.
   PubMed Web of Science ®Google Scholar
• Beier J, Beeh KM, Brookman L, Peachey G, Hmissi A, Pascoe S. Bronchodilator effects of indacaterol and formoterol in patients with COPD. Pulm Pharmacol Ther 2009; 22:492–496.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease NHLBI/WHO workshop report. Bethseda, National Heart, Lung, and Blood Institute. April 2001(updated 2005). Available at www.gold.copd.com (accessed 14 Jan 2010).
   Google Scholar
• Roca J, Whipp BJ, Agusti AGN, Anderson SD, Casaburi R, Cotes JE, Donner CF, Estenne M, Folgering H, Higenbottam TW, Killian KJ, Palange P, Patessio A, Prefaut C, Sergysels R, Wagner PD, Weisman I. Clinical exercise testing with reference to lung diseases: indications, standardization and interpretation strategies. ERS Task Force on Standardization of Clinical Exercise Testing. European Respiratory Society. Eur Respir J 1997; 10:2662–2689.
   PubMed Web of Science ®Google Scholar
• O'Donnell DE, Fluge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, Make B, Magnussen H. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23:832–840.
   PubMed Web of Science ®Google Scholar
• Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85:751–758.
   PubMed Web of Science ®Google Scholar
• Witek TJ, Jr., Mahler DA. Meaningful effect size and patterns of response of the transition dyspnea index. J Clin Epidemiol 2003; 56:248–255.
   PubMed Web of Science ®Google Scholar
• Witek TJ, Jr., Mahler DA. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J 2003; 21:267–272.
   PubMed Web of Science ®Google Scholar
• Borg GAV. Psychophysical basis of perceived exertion. Med Sci Sports Exerc 1982; 14:377–381.
   PubMed Web of Science ®Google Scholar
• Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. General considerations for lung function testing. Eur Respir J 2005; 26:153–161.
   PubMed Web of Science ®Google Scholar
• Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CPM, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. Standardisation of spirometry, Eur Respir J 2005; 26:319–338.
   PubMed Web of Science ®Google Scholar
• Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, Casaburi R, Crapo R, Enright P, van der Grinten CPM, Gustafsson P, Hankinson J, Jensen R, Johnson D, MacIntyre N, McKay R, Miller MR, Navajas D, Pellegrino R, Viegi G. Standardisation of the measurement of lung volumes Eur Respir J 2005; 26: 511–522.
   PubMed Web of Science ®Google Scholar
• Diaz O, Villafranca C, Ghezzo H, Borzone G, Leiva A, Milic-Emil J, Lisboa C. Role of inspiratory capacity on exercise tolerance in COPD patients with and without tidal expiratory flow limitation at rest. Eur Respir J 2000; 16:269–275.
   PubMed Web of Science ®Google Scholar
• Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 153:967–975.
   PubMed Web of Science ®Google Scholar
• O'Donnell DE, Lam M, Webb KA. Measurements of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158:1557–1565.
   PubMed Web of Science ®Google Scholar
• O'Donnell DE, Sciurba F, Celli B, Mahler DA, Webb KA, Kalberg CJ, Knobil K. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest 2006; 130:647–656.
   PubMed Web of Science ®Google Scholar
• Mahler DA, Witek TJ Jr. The MCID of the transition dyspnea index is a total score of one unit. COPD 2005; 2:99–103.
   PubMedGoogle Scholar
• Rennard S, Bantje T, Centanni S, Chanez P, Chuchalin A, D'Urzo A, Kornmann O, Perry S, Jack D, Owen R, Higgins M. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med 2008; 102:1033–1044.
   PubMed Web of Science ®Google Scholar